ATE516497T1 - Screening für funktionshomologien - Google Patents

Screening für funktionshomologien

Info

Publication number
ATE516497T1
ATE516497T1 AT01914718T AT01914718T ATE516497T1 AT E516497 T1 ATE516497 T1 AT E516497T1 AT 01914718 T AT01914718 T AT 01914718T AT 01914718 T AT01914718 T AT 01914718T AT E516497 T1 ATE516497 T1 AT E516497T1
Authority
AT
Austria
Prior art keywords
screening
pathways
analysis
identification
rapid identification
Prior art date
Application number
AT01914718T
Other languages
English (en)
Inventor
Ellen Berg
Eugene Butcher
Jennifer Melrose
Ivan Plavec
Original Assignee
Asterand Acquisition Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Asterand Acquisition Llc filed Critical Asterand Acquisition Llc
Application granted granted Critical
Publication of ATE516497T1 publication Critical patent/ATE516497T1/de

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • G01N33/5047—Cells of the immune system
    • G01N33/505—Cells of the immune system involving T-cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/502—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
    • G01N33/5023—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects on expression patterns
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/502—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
    • G01N33/5041—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects involving analysis of members of signalling pathways
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • G01N33/5047—Cells of the immune system
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • G01N33/5061—Muscle cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • G01N33/5064—Endothelial cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5091—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing the pathological state of an organism
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6863—Cytokines, i.e. immune system proteins modifying a biological response such as cell growth proliferation or differentiation, e.g. TNF, CNF, GM-CSF, lymphotoxin, MIF or their receptors
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6863—Cytokines, i.e. immune system proteins modifying a biological response such as cell growth proliferation or differentiation, e.g. TNF, CNF, GM-CSF, lymphotoxin, MIF or their receptors
    • G01N33/6866—Interferon
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6863—Cytokines, i.e. immune system proteins modifying a biological response such as cell growth proliferation or differentiation, e.g. TNF, CNF, GM-CSF, lymphotoxin, MIF or their receptors
    • G01N33/6869—Interleukin
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6872—Intracellular protein regulatory factors and their receptors, e.g. including ion channels
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/02—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving viable microorganisms
    • C12Q1/04—Determining presence or kind of microorganism; Use of selective media for testing antibiotics or bacteriocides; Compositions containing a chemical indicator therefor
    • C12Q1/06—Quantitative determination
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/52—Assays involving cytokines
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/70503—Immunoglobulin superfamily, e.g. VCAMs, PECAM, LFA-3
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/10—Screening for compounds of potential therapeutic value involving cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2510/00—Detection of programmed cell death, i.e. apoptosis
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N5/00—Analysing materials by weighing, e.g. weighing small particles separated from a gas or liquid

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Chemical & Material Sciences (AREA)
  • Urology & Nephrology (AREA)
  • Cell Biology (AREA)
  • General Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Pathology (AREA)
  • Food Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Toxicology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Physiology (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Treatment Of Sludge (AREA)
AT01914718T 2000-03-06 2001-03-06 Screening für funktionshomologien ATE516497T1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US18697600P 2000-03-06 2000-03-06
US19567200P 2000-04-07 2000-04-07
PCT/US2001/007190 WO2001067103A1 (en) 2000-03-06 2001-03-06 Function homology screening

Publications (1)

Publication Number Publication Date
ATE516497T1 true ATE516497T1 (de) 2011-07-15

Family

ID=26882614

Family Applications (1)

Application Number Title Priority Date Filing Date
AT01914718T ATE516497T1 (de) 2000-03-06 2001-03-06 Screening für funktionshomologien

Country Status (7)

Country Link
US (6) US6656695B2 (de)
EP (1) EP1269187B8 (de)
JP (1) JP4798921B2 (de)
AT (1) ATE516497T1 (de)
AU (2) AU2001240074B2 (de)
CA (1) CA2400989C (de)
WO (1) WO2001067103A1 (de)

Families Citing this family (55)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050221280A1 (en) * 1998-02-02 2005-10-06 Odyssey Thera, Inc. Protein-protein interactions for pharmacological profiling
US6763307B2 (en) * 2000-03-06 2004-07-13 Bioseek, Inc. Patient classification
US6656695B2 (en) * 2000-03-06 2003-12-02 Bioseek, Inc. Biomap characterization of biologically active agents
US7521192B2 (en) * 2001-04-18 2009-04-21 Rigel Pharmaceuticals, Inc. EDG: modulators of lymphocyte activation and migration
DE60233574D1 (de) 2001-07-10 2009-10-15 Univ R Verfahren und zusammensetzungen zum nachweis des aktivierungszustands multipler proteine in einzelzellen
US7393656B2 (en) * 2001-07-10 2008-07-01 The Board Of Trustees Of The Leland Stanford Junior University Methods and compositions for risk stratification
US7695926B2 (en) 2001-07-10 2010-04-13 The Board Of Trustees Of The Leland Stanford Junior University Methods and compositions for detecting receptor-ligand interactions in single cells
US7381535B2 (en) 2002-07-10 2008-06-03 The Board Of Trustees Of The Leland Stanford Junior Methods and compositions for detecting receptor-ligand interactions in single cells
WO2003017177A2 (en) * 2001-08-13 2003-02-27 Beyong Genomics, Inc. Method and system for profiling biological systems
US20070135997A1 (en) * 2003-04-23 2007-06-14 Evangelos Hytopoulos Methods for analysis of biological dataset profiles
US20070087344A1 (en) * 2003-04-23 2007-04-19 Bioseek, Inc. Methods for characterizing signaling pathways and compounds that interact therewith
WO2005020125A2 (en) * 2003-08-20 2005-03-03 Bg Medicine, Inc. Methods and systems for profiling biological systems
JP2007503841A (ja) * 2003-09-03 2007-03-01 バイオシーク インコーポレイティッド 薬剤作用を決定するための細胞ベースのアッセイ法
EP2280286A1 (de) * 2003-09-15 2011-02-02 Oklahoma Medical Research Foundation Verfahren zur Verwendung von Zytokin-Assays zur Diagnose, Behandlung und Beurteilung von Systemischem Lupus Erythematosus
US20050142608A1 (en) * 2003-09-22 2005-06-30 Yokogawa Electric Corporation Screening method and device, and new drug screening method and device
JP2007527239A (ja) * 2004-02-27 2007-09-27 バイオシーク インコーポレイティッド 喘息およびアトピーの生物学的データセットプロファイリング方法
US7374536B1 (en) 2004-04-16 2008-05-20 Taylor Colin R Method for analysis of pain images
CA2587903A1 (en) * 2004-11-17 2006-05-26 Amgen Fremont Inc. Fully human monoclonal antibodies to il-13
AU2005312065A1 (en) * 2004-11-30 2006-06-08 Cell Networx Llc Cellular signaling pathway based assays, reagents and kits
EP1842147A2 (de) * 2005-01-24 2007-10-10 The Board of Trustees of The Leland Stanford Junior University Verfahren zur modellierung von zellsignalisierungssystemen mithilfe von bayes-netzwerken
AU2006216514C1 (en) * 2005-02-25 2012-09-27 Isis Pharmaceuticals, Inc. Compositions and their uses directed to IL-4R alpha
EP1872293A4 (de) * 2005-03-28 2010-01-06 Bioseek Inc Profilierung biologischer datensätze für kardiovaskuläre erkrankungen und kardiovaskuläre entzündungen
US20080279441A1 (en) * 2005-03-29 2008-11-13 Yuichiro Matsuo Cell-Image Analysis Method, Cell-Image Analysis Program, Cell-Image Analysis Apparatus, Screening Method, and Screening Apparatus
US8426146B2 (en) * 2005-06-03 2013-04-23 University of Pittsburgh—of the Commonwealth System of Higher Education Multiparameteric method for assessing immune system status
CA2621439A1 (en) * 2005-09-09 2007-03-15 The University Of Chicago Methods and compositions for diagnosis and immunotherapy of pollen allergy
AU2006299345A1 (en) * 2005-10-03 2007-04-12 Isis Pharmaceuticals, Inc. Combination therapy using budesonide and antisense oligonucleotide targeted to IL4-receptor alpha
EP1969143A4 (de) * 2005-12-20 2009-07-22 Isis Pharmaceuticals Inc Auf il-4-rezeptor alpha als ziel gerichtete doppelsträngige nukleinsäuremoleküle
JP2009526519A (ja) * 2006-01-17 2009-07-23 セルーメン、インコーポレイテッド 生物学的システム応答の予測方法
US20080051335A1 (en) * 2006-05-02 2008-02-28 Kleiner Lothar W Methods, compositions and devices for treating lesioned sites using bioabsorbable carriers
CA2652562C (en) 2006-05-17 2015-05-12 Cellumen, Inc. Method for automated tissue analysis
EP2023874A4 (de) * 2006-06-02 2009-07-08 Bioseek Inc Verfahren zur identifizierung von wirkstoffen und ihre verwendung zur prävention von restenose
US8603530B2 (en) 2006-06-14 2013-12-10 Abbott Cardiovascular Systems Inc. Nanoshell therapy
US8048448B2 (en) * 2006-06-15 2011-11-01 Abbott Cardiovascular Systems Inc. Nanoshells for drug delivery
US20100093613A1 (en) * 2007-03-09 2010-04-15 Kunkel Eric J Methods for identifying agents and their use for the prevention or stabilization of fibrosis
EP2152944A4 (de) 2007-03-30 2010-12-01 Bioseek Inc Verfahren zur klassifizierung toxischer mittel und gegenmittel
US20090099784A1 (en) * 2007-09-26 2009-04-16 Ladd William M Software assisted methods for probing the biochemical basis of biological states
GB0800938D0 (en) 2008-01-18 2008-02-27 Ge Healthcare Uk Ltd Multiplex cell signalling assay
US20090269773A1 (en) * 2008-04-29 2009-10-29 Nodality, Inc. A Delaware Corporation Methods of determining the health status of an individual
US20090291458A1 (en) * 2008-05-22 2009-11-26 Nodality, Inc. Method for Determining the Status of an Individual
US8399206B2 (en) 2008-07-10 2013-03-19 Nodality, Inc. Methods for diagnosis, prognosis and methods of treatment
WO2010006291A1 (en) 2008-07-10 2010-01-14 Nodality, Inc. Methods for diagnosis, prognosis and treatment
US20100099109A1 (en) * 2008-10-17 2010-04-22 Nodality, Inc., A Delaware Corporation Methods for Analyzing Drug Response
GB0908788D0 (en) * 2009-05-21 2009-07-01 Univ Southampton Tissue analysis
US8765370B2 (en) * 2009-06-11 2014-07-01 Scinopharm Taiwan, Ltd Inhibition-based high-throughput screen strategy for cell clones
GB0916585D0 (en) 2009-09-21 2009-10-28 Plasticell Ltd Apparatus and method for processing cell culture data
US20120034613A1 (en) * 2010-08-03 2012-02-09 Nse Products, Inc. Apparatus and Method for Testing Relationships Between Gene Expression and Physical Appearance of Skin
ES2739623T3 (es) 2011-03-17 2020-02-03 Cernostics Inc Sistemas y composiciones para diagnosticar el esófago de Barrett y métodos para usarlos
US20160139109A1 (en) * 2013-06-26 2016-05-19 Valitacell Limited A Method of Determining or Predicting a Characteristic of a Cell
US20150198584A1 (en) * 2014-01-14 2015-07-16 Asedasciences Ag Identification of functional cell states
GB201511419D0 (en) * 2015-06-30 2015-08-12 Ge Healthcare Uk Ltd The use of bioinformatic data in autolobous cell therapies
CN108763864B (zh) * 2018-05-04 2021-06-29 温州大学 一种评价生物通路样本状态的方法
AU2020295989A1 (en) * 2019-06-18 2022-01-20 The Scripps Research Institute Methods and compositions for treating inflammatory conditions
US11600388B2 (en) 2019-08-19 2023-03-07 MediSync Inc. Artificial intelligence systems that incorporate expert knowledge related to hypertension treatments
US20240337647A1 (en) 2021-07-26 2024-10-10 Asedasciences Ag Improved methods for identification of functional cell states
EP4431090A1 (de) 2023-03-15 2024-09-18 Istesso 1 Limited Solfonamide als mitochondriale komplex-i-modulator-verbindungen

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4568649A (en) 1983-02-22 1986-02-04 Immunex Corporation Immediate ligand detection assay
JPH03504330A (ja) * 1988-12-14 1991-09-26 アメリカ合衆国 ヒト肝上皮細胞系のための細胞培地
US5464764A (en) 1989-08-22 1995-11-07 University Of Utah Research Foundation Positive-negative selection methods and vectors
AU6823694A (en) * 1993-04-30 1994-11-21 Pacific Northwest Research Foundation Dna profiles as an indicator of cellular redox potential and cancer risk
ATE162216T1 (de) * 1993-05-17 1998-01-15 Amersham Int Plc Vorrichtung und verfahren zum nachweis zellularer und biochemischer prozesse
WO1995006132A2 (en) * 1993-08-27 1995-03-02 Myco Pharmaceuticals, Incorporated Identifying biologically active agents through culture color change
JPH10513048A (ja) * 1995-01-23 1998-12-15 マイクロサイド・ファーマシューティカルズ・インコーポレーテッド 生体分子の変調剤のためのスクリーニング
US5569588A (en) 1995-08-09 1996-10-29 The Regents Of The University Of California Methods for drug screening
US5777888A (en) 1995-08-09 1998-07-07 Regents Of The University Of California Systems for generating and analyzing stimulus-response output signal matrices
US6013437A (en) 1996-11-12 2000-01-11 Qbi Enterprises, Ltd. Method for identifying translationally regulated genes
US5981472A (en) * 1997-02-21 1999-11-09 Dx/Ibr Corporation Methods for treating diseases
US5994076A (en) 1997-05-21 1999-11-30 Clontech Laboratories, Inc. Methods of assaying differential expression
US6004755A (en) 1998-04-07 1999-12-21 Incyte Pharmaceuticals, Inc. Quantitative microarray hybridizaton assays
US5965352A (en) * 1998-05-08 1999-10-12 Rosetta Inpharmatics, Inc. Methods for identifying pathways of drug action
US6518035B1 (en) * 1998-06-02 2003-02-11 Rosetta Inpharmatics, Inc. Targeted methods of drug screening using co-culture methods
US6146830A (en) 1998-09-23 2000-11-14 Rosetta Inpharmatics, Inc. Method for determining the presence of a number of primary targets of a drug
US6203987B1 (en) * 1998-10-27 2001-03-20 Rosetta Inpharmatics, Inc. Methods for using co-regulated genesets to enhance detection and classification of gene expression patterns
US6801859B1 (en) * 1998-12-23 2004-10-05 Rosetta Inpharmatics Llc Methods of characterizing drug activities using consensus profiles
WO2000052467A1 (en) 1999-03-02 2000-09-08 The University Of Dundee Methods of determining altered ndpk functions
WO2001051664A2 (en) 2000-01-12 2001-07-19 Dana-Farber Cancer Institute, Inc. Method of detecting and characterizing a neoplasm
US7266458B2 (en) 2000-03-06 2007-09-04 Bioseek, Inc. BioMAP analysis
US6763307B2 (en) 2000-03-06 2004-07-13 Bioseek, Inc. Patient classification
US6656695B2 (en) 2000-03-06 2003-12-02 Bioseek, Inc. Biomap characterization of biologically active agents
EP1221618A1 (de) 2000-11-29 2002-07-10 GeneScan Europe AG Diagnoseverfahren für allergische Erkrankungen
EP2152944A4 (de) * 2007-03-30 2010-12-01 Bioseek Inc Verfahren zur klassifizierung toxischer mittel und gegenmittel

Also Published As

Publication number Publication date
EP1269187B8 (de) 2011-10-05
EP1269187B1 (de) 2011-07-13
AU4007401A (en) 2001-09-17
EP1269187A1 (de) 2003-01-02
WO2001067103A9 (en) 2002-12-27
US20040157269A1 (en) 2004-08-12
AU2001240074B2 (en) 2006-02-23
US10018621B2 (en) 2018-07-10
US20130266967A1 (en) 2013-10-10
CA2400989A1 (en) 2001-09-13
CA2400989C (en) 2014-09-30
US20030113807A1 (en) 2003-06-19
WO2001067103A1 (en) 2001-09-13
US8467970B2 (en) 2013-06-18
EP1269187A4 (de) 2005-11-09
US20040063088A1 (en) 2004-04-01
JP2003527110A (ja) 2003-09-16
US20080070271A1 (en) 2008-03-20
US6656695B2 (en) 2003-12-02
JP4798921B2 (ja) 2011-10-19
US7912651B2 (en) 2011-03-22
US20080064056A1 (en) 2008-03-13

Similar Documents

Publication Publication Date Title
ATE516497T1 (de) Screening für funktionshomologien
DE69738996D1 (de) Miniaturisierte zellenanordnung und verfahren und vorrichtung zum screening mittels zellen
ATE346156T1 (de) Umkehrtransfektionsverfahren
ATE333517T1 (de) Verfahren und sondenset zur erkennung von krebs
ATE389008T1 (de) Verfahren und vorrichtung zum züchten und/oder behandeln von zellen
WO2004055519A3 (en) Specific markers for pancreatic cancer
EA200501772A1 (ru) Способы измерения экспрессии генов из фиксированного и залитого в парафин образца ткани
ATE515575T1 (de) Verfahren und sonden für den nachweis von krebs
DE60233574D1 (de) Verfahren und zusammensetzungen zum nachweis des aktivierungszustands multipler proteine in einzelzellen
ATE526580T1 (de) Methode zum sichten von mutierten zellen
DE69822206D1 (de) Erkenntnisse der genomforschung für die suche nach neuartigen wirkstoffen
ATE409236T1 (de) Derivatisierte nukleinsäuren und deren verwendung
PL354423A1 (en) Method of biological fluid sampling and making corresponding analyte measurements as well as an electrochemical cell, apparatus and system therefor
DK1032705T3 (da) Probearrays og fremgangsmåder til at benytte probearrays til at skelne mellem DNA
ATE490466T1 (de) Als interne funktionskontrolle in tests zum nachweis von seltenen zellen verwendete markierte zellen
DE69941044D1 (de) Methoden, Apparat und Computerprogramm zur quantitativen Bestimmung von Nukleinsäurensequenzen in Proben unter Verwendung von Standardkurven und Abschätzungen von Amplifikationsverhältnissen
ATE264922T1 (de) Verfahren zur erkennung von klonalen populationen von transformierten zellen in einer genomisch heterogenen zellulären probe
ATE239274T1 (de) Proteom-analyse zum charakterisieren von auf- und abgeregelten proteinen in biologischen proben
ATE428928T1 (de) Verfahren zur einführung von heterologischen zellen in fische
WO2002066975A3 (en) Tissue-based water quality biosensors for detecting chemical warfare agents
DE50204289D1 (de) Vorrichtung und verfahren zur selektion von selbstbeweglichen biologischen spezies, insbesondere von samenzellen
WO2004013603A3 (en) A method of sample preparation for atom probes and source of specimens
WO2003095624A3 (en) Liver inflammation predictive genes
WO2004037160A3 (en) In vitro test for studying compound predicting pharmacologic and/or pharmacokinetic and/or pharmacodynamic parameters of a compound
ATE256120T1 (de) Reagentien für cyp2d fluoreszenztest

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties